Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial by Mayne, KM, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Wanner, C, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W

“…</p> <br> <p><strong>Results:</strong> The strongest predictors of hospitalization were N-terminal prohormone of brain natriuretic peptide, poor mobility and diabetes; then eGFR and other comorbidities. …”